Connect Biopharma Holdings (CNTB) Total Equity: History & Chart

Connect Biopharma Holdings Limited(CNTB)

Biotechnology · San Diego, CA

$0.90+0.00 (+0.11%)

Delayed quote: Oct 6, 2026, 10:50 AM EDT

About Connect Biopharma Holdings Limited

Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody. This candidate is currently in Phase IIb clinical trials, targeting inflammatory allergic diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Additionally, Connect Biopharma's pipeline includes CBP-307, a small molecule designed to modulate sphingosine 1-phosphate receptor 1. This receptor plays a crucial role in regulating T cell movement from lymph nodes into the bloodstream. CBP-307 is in Phase II development for treating autoimmune-related inflammatory disorders. Another preclinical-stage asset, CBP-174, is an orally administered small molecule histamine receptor 3 antagonist, being investigated for chronic pruritus (itch) associated with skin inflammation. The portfolio also features CBP-233, a humanized antibody in preclinical development that targets interleukin-33, a cytokine recognized for its involvement in T helper 2 inflammation. Established in 2012, the company maintains its headquarters in Taicang, China.

San Diego, CA

64 employees

www.connectbiopharma.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Barry D. Quart

View full financials

Total Equity

Basis: latest reported fiscal quarter. Source: stored company filings; unavailable inputs remain N/A.

The latest quarterly total equity is $26.86M. Total equity, also called shareholders' equity, is assets minus liabilities. The book value in P/B is the part attributable to common shareholders: total equity minus preferred stock.

Total Equity

CNTB Total Equity

$26.86M

Reported quarterly total equity; no daily interpolation. Q2 FY2026 (2026-06-30): $26.86M.

+238.37% over 10Y

CNTB P/B Ratio

Full P/B Ratio page

P/B Ratio

CNTB P/B Ratio Chart

2.11

FMP quote market capitalization / book value attributable to common shareholders (matching reported total stockholders equity minus preferred stock) Quote observation: 2026-10-06T14:51:30.160Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.

Quarterly Total Equity History

Period	Total Equity	QoQ Growth	YoY Growth
Q2 FY2026Period end 2026-06-30	$26.86M	N/A	N/A
Q4 FY2025Period end 2025-12-31	$41.98M	N/A	N/A
Q2 FY2025Period end 2025-06-30	$71.34M	N/A	N/A
Q4 FY2024Period end 2024-12-31	$92.17M	N/A	N/A
Q2 FY2024Period end 2024-06-30	$110.48M	N/A	N/A
Q4 FY2023Period end 2023-12-31	$101.50M	N/A	N/A
Q2 FY2023Period end 2023-06-30	$17.69M	N/A	N/A
Q4 FY2022Period end 2022-12-31	$23.00M	N/A	N/A
Q2 FY2022Period end 2022-06-30	$31.83M	N/A	N/A
Q4 FY2021Period end 2021-12-31	$42.75M	N/A	N/A
Q2 FY2021Period end 2021-06-30	$49.81M	N/A	N/A
Q4 FY2020Period end 2020-12-31	($24.03M)	N/A	N/A
Q4 FY2019Period end 2019-12-31	($43.27M)	N/A	N/A
Q2 FY2019Period end 2019-06-30	($31.34M)	N/A	N/A
Q4 FY2018Period end 2018-12-31	($19.41M)	N/A	N/A

Growth uses unique fiscal quarters. Missing or ambiguous prior periods render N/A.